logo
  Join        Login             Stock Quote

Bristol Myers Squibb (BMY), Pfizer (PFE) Say ELIQUIS Approved in Europe

 November 20, 2012 02:40 PM
 


(By Balachander) Bristol Myers Squibb Co. (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced approval from the European Commission for ELIQUIS for the prevention of strokes in patients with nonvalvular atrial fibrillation.

In 2007, the companies entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-Myers Squibb.

ELIQUIS is the only oral anticoagulant that has demonstrated superior risk reduction versus warfarin in the three important outcomes of stroke and systemic embolism, major bleeding, and all-cause mortality, the companies said.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

"This is the first regulatory approval in any market for ELIQUIS for stroke prevention in patients with nonvalvular atrial fibrillation," Bristol Myers and Pfizer said.

In May 2011, the companies announced the first regulatory approval for ELIQUIS in the 27 countries of the European Union for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery, at a dose of 2.5 mg twice daily. 

According to the companies, ELIQUIS is an oral direct Factor Xa inhibitor, part of a new therapeutic class. By inhibiting Factor Xa, a key blood clotting protein, ELIQUIS prevents thrombin generation and blood clot formation.

[Related -Six Stocks That Could Get An October Bump From The FDA]

"We are confident in ELIQUIS and its differentiated profile and believe it has the potential to transform the standard of care in stroke prevention in nonvalvular atrial fibrillation," commented said Pfizer CEO Ian Read.

ELIQUIS is not yet approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation outside of the EU.

On Tuesday, BMY shares inched up 0.22 percent to trade at $32.08 and PFE shares added 0.27 percent to trade at $24.20.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageSolar and Biotechnology Stocks Rally as Rational Exuberance Dominates

Solar stocks are rallying due to positive earnings and deals. Biotechnology stocks are also rallying due to read on...

article imageA Hefty Upside Surprise For February Payrolls

Private payrolls increased substantially more than expected in February, delivering an encouraging dose of read on...

article imageWarren Buffett’s Stellar Record In Defying Economic Gravity

One of the more intriguing observations in Berkshire Hathaway’s new letter to shareholders is Warren read on...

article imageDebate Around the 2015 Rate Hike Intensifies

Following Janet Yellen's Senate Banking Committee testimony, the Fed seems to be quite deliberate in read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Bristol-Myers (BMY): Blockbusters Ahead?
More Articles on: Medical , Europe



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.